In addition to PD-1 inhibitors, PD-L1 inhibitors (atezolizumab and sugemalimab) combined with CT also showed amazing results in the treatment of patients with driver-gene-negative advanced non-squamous NSCLC [27,28,29]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.